Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus DYCLOPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus DYCLOPRO.
ANAPROX vs DYCLOPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
50 mg intravenously every 8 hours
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Category C
Category C
NSAID
NSAID